Category - Developments

Developments

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Ocular Therapeutix (NASDAQ:OCUL) has dosed the first patients in its Phase 3 efficacy trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC). DEXTENZA is a corticosteroid that is FDA-approved...

September 24, 2019

Developments

MDACC begins dosing pancreatic cancer patients in Phase 1b trial of Soricimed’s SOR-C13

Closely-held Soricimed reported that The University of Texas MD Anderson Cancer Center (MDACC) has begun dosing the first cohort of three late-stage pancreatic cancer patients in its investigator-initiated trial of SOR...

September 24, 2019

Developments

Zenabis receives final license amendment for Zenabis Atholville site

Zenabis Global (TSX:ZENA) has received the licensing of Phase 2C – Part 2 at its Zenabis Atholville site in New Brunswick for an additional 3,000 kg of licensed annual cultivation capacity of cannabis. The amendment...

September 23, 2019

Developments

BeyondSpring to present superior product data in breast cancer neutropenia prevention

BeyondSpring’s (NASDAQ:BYSI) poster with findings from its Study 106 has been accepted for presentation at this year’s European Society for Medical Oncology Congress in Barcelona on Sept. 28. In Study 106, BeyondSpring...

September 23, 2019

Developments

Aerie Pharma receives positive CHMP opinion for Rhokiinsa in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Aerie Pharmaceuticals’ (NASDAQ:AERI) marketing authorization application (MAA) for Rhokiinsa solution. The...

September 20, 2019

Developments

BriaCell presents remarkable responder data in combo study with KEYTRUDA

Dr. William Williams, president and CEO of BriaCell Therapeutics (TSX-V:BCT; OTCQB:BCTXF) presented clinical updates of its Phase 1/2a clinical trial of Bria-IMT, its lead drug candidate, in a combination study with...

September 19, 2019

Developments

Zynerba Pharma reports positive topline Phase 2 Zygel efficacy data

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline efficacy results, along with safety profile issues, from its open label Phase 2 study assessing the safety and efficacy of Zygel in developmental and...

September 19, 2019

Developments

Zenabis outperforms revised cannabis design capacity by 41% in August

Zenabis Global’s (TSX:ZENA) cultivation output in August 2019 was 1,996 kg of dried cannabis, 40.9% greater than its revised design capacity and 26.4% greater than its Aug. 6 revised forecast output of 1,579 kg of dried...

September 18, 2019

Developments

Anika Therapeutics launches TACTOSET bone repair therapy in the U.S.

Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects. TACTOSET is an injectable, HA...

September 18, 2019

Developments

FDA approves Kadmon Holdings’ generic Wilson’s disease drug

The FDA approved Kadmon Holdings’ (NYSE:KDMN) generic trientine hydrochloride capsules for the treatment of Wilson’s disease patients who are intolerant of penicillamine. Wilson’s disease is a genetic disorder caused by...

September 18, 2019

Category - Developments

Subscribe